

Recent developments on Novel Heterocyclic compounds Thiadiazoles and Heterocyclic compounds for Covid 19 Targets in Drug Discovery


Abstract

This article mainly reviews the recent developments in the synthesis of novel heterocyclic compounds such as 1,3,4-Thiadiazoles and also recent development of drug molecules for the treatment of Covid 19. The Thiadiazole heterocycle and its derivatives are the most important class of compounds among various heterocyclic compounds due to their wide range of biological activities and pharmaceutical importance. Thiadiazole moiety exists as a principal structural pharmacophore in the combination of drug categories such as antimicrobial, anti-inflammatory, analgesic, antiepileptic, antiviral, antineoplastic, antitubercular agents. In this review article, we have attempted to show various synthetic procedures of thiadiazole derivatives along with their pharmacological activities and also the recent studies on Antiviral targets for the discovery of new drugs to combat Covid19 like viruses.


Introduction

Heterocyclic compounds are the cyclic compounds possessing one or more atom(s) of other elements along with the carbon atoms in the ring system. Nitrogen, sulfur, oxygen are some of the most commonly used heteroatoms.


Thiadiazole is a five-membered cyclic system possessing hydrogen binding domain, the sulfur atom, and nitrogen atoms. There are four types of thiadiazoles: 1,3,4-, 1,2,4-, 1,2,5- and 1,2,3-thiadiazole. 1, 3, 4-thiadiazoles have become a versatile class of heterocycles and a great area for academicians and researchers due to their wide range of biological activity.




1,3,4 Thiadiazole



1,2,5-Thiadiazole




1,2,4-Thiadiazole




1,2,3- Thiadiazole


A number of thiadiazole-containing drugs are reported in the literature and marketed as shown below.




acetazolamide



methazolamide



Sulfamethizole




Megazol


1,3,4-Thiadiazole and its reactivity

Several researchers have used different synthetic strategies to obtain the desired target thiadiazole. Some of the synthetic methodologies are reviewed in this article and shown below.


The ring nitrogens react with electrophiles to afford either 1,3,4-thiadiazolium salts or 1,3,4thiadiazol-2(3H)-ones depending on the tautomeric stability of the substituents at the C-2 or C-5 positions. 2-Amino-1,3,4- thiadiazole reacts with chloroacetone to furnish the N-alkylated thiadiazolimine. Reaction with chloroacetone to provide the alkylated thiadiazolimine and reaction with trimethylsilyl methyl trifluoromethane sulfonate to give 1,3,4-thiadiazolium salts respectively.




Due to the low electron density at the carbon atoms in 1,3,4-thiadiazole such reactions as nitration, sulphonation, acetylation, halogenations normally do not take place. C-Acylation can be accomplished via rearrangement of intermediate N-acylthiadiazolium salts while radical halogenation can give chlorinated or brominated 2-halo-5-substituted thiadiazoles. 2-aminosubstituted 1,3,4-thiadiazoles react with bromine in acetic acid to give the 5-bromo derivatives as shown in the following reaction (reference provided).




Halo-substituted thiadiazoles are highly activated and react with a variety of nucleophiles. Carbon-based nucleophiles such as malonate have been used in the synthesis of 2-substituted thiadiazoles. When 2-chlorothiadiazole was treated with ethyl acetate in the presence of sodium hexamethyldisilazane (NaHMDS), the 5-phenyl-1,3,4-thiadiazol-2-yl acetic ester was obtained as shown in the following reaction.




Reaction of various alkylating agents with unsubstituted and 5-substituted thiadiazoles yield 3-alkyl-1,3,4-thiadiazolium salts. These salts were deprotonated with ethoxide to produce carbenes which were then trapped with aromatic isocyanates to yield spirocyclic compounds as mentioned below.




According to **Azaam M M** et al., (2018), an α -aminophosphonate containing thiadiazole was synthesized by reacting 2-amino-5-methyl-1,3,4-thiadiazole with various aldehydes, triphenyl phosphite and mixed valence Cu(I)/Cu(II) inorganic coordination polymer as a catalyst. The products were characterized and their anticancer activity was carried out on human hepatocellular carcinoma and breast adenocarcinoma cell lines using MTT assay method. These compounds were found to show good anticancer activity.




In another report, **Abdelhamid A O** et al., (2016) synthesized some 1, 3, 4-thiadiazole derivatives by the reaction of hydrazonoyl halides with 3-(1H-indol-2-yl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide, hydrazonoyl halides with N'-(1-(1H-indol-3-yl)ethylidene)-2-cyanoacetohydrazide to form 1,3,4-thiadiazole derivatives. The compounds have been characterized and screened for their antitumor activity against the MCF-7 human breast carcinoma cell line. These compounds are novel and found to show good activity.




In another approach, **Amir M** et al., in 2017 synthesized 6-substituted-1, 2, 4-triazolo [3, 4-b]-1, 3, 4-thiadiazole from naphthoxy acetic acid. The products were characterized and evaluated for their anti-inflammatory activity. These compounds were reported to be showing promising activity.




While **Patel H M, Noolvi M N, Sethi N S, Gadad A K, Cameotra S S** et al., in 2017 synthesized imidazo [2, 1-b][1, 3, 4] thiadiazole derivatives and evaluated for their antitubercular activity.



Quinazolin-4 (3H)-one derivatives containing a 1, 2, 4-triazolo [3, 4-b][1, 3, 4] thiadiazole moiety were synthesized by **Lv X, Yang L, Fan Z, Bao X** et al., in 2017, characterized by the spectral data and evaluated their antimicrobial activities.




$2\text{N}_2\text{O}_4 \cdot \text{H}_2\text{O}$
 CS_2, KOH
 Ethanol




$\text{R}^1 = \text{Phenyl, Methoxy}$

New 1-thia-4-azaspiro [4.5] decane, derived from thiazolopyrimidine and 1, 3, 4 thiadiazole thioglycosides were synthesized by **Flefel E M** et.al., in 2017 and evaluated their anticancer activity. These compounds were found to show interesting activity.


Kumari R, Sharma B B, Dubey V et al., in 2017 synthesized 1, 3,4-thiadiazole derivatives and evaluated for their anti-inflammatory activities.




Kothawade P, Bhalerao R, Kulkarni G et al., in 2017 synthesized the following 1, 3, 4-thiadiazole derivatives and evaluated for its antidiabetic and antioxidant activity. The aryl carboxylic acid is treated with thiosemicarbazide in ethanol in the presence of catalytic quantity of sulfuric acid to obtain the respective thiadiazole.



Previously in a slightly different approach, **Abdo N Y, Kamel M M. et al.**, in 2015 synthesized 1, 3, 4-thiadiazole derivatives and evaluated for its anticancer activity.




Madhavi, B. and Veera Raghava Sharma, G. have been focusing on the synthesis of novel thiazolidinone analogs as shown in the following scheme for their biological activity studies including their role in treating viral diseases such as Covid 19 and similar viruses.




Antibacterial and antifungal activity

Aggarwal et al synthesized novel nalidixic acid-based 1,3,4-thiadiazoles and demonstrated their antimicrobial activity. The bacterial strain used included gram-positive bacteria, *Staphylococcus aureus* and *Bacillus subtilis*, and Gram-negative bacteria, namely *Escherichia coli*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*. Compound with 1,4-bis(methylene)benzene group as a spacer between two 1,3,4-thiadiazoles showed remarkable antibacterial activity (MIC, 31.25–125 $\mu\text{g}/\text{mL}$) against all the tested organisms.




R- $-(\text{CH}_2)_0$; $-(\text{CH}_2)_4$; $-(\text{CH}_2)_6$; $-(\text{CH}_2)_8$; $-\text{CH}_2\text{C}_6\text{H}_4\text{CH}_2-$


Teja et al synthesized some novel thiadiazolo[2,3]imidazo[4,5-b]quinoxaline derivatives and evaluated their antimicrobial activity against gram positive (*S. aureus* and *Bacillus cereus*) and Gram-negative bacteria (*Escherichia coli* and *Pseudomonas aeruginosa*) by paper disc diffusion method. The minimum inhibitory concentrations (MIC) of the compounds were also determined by using the agar streak dilution method. Ciprofloxacin was used as reference drug. Many compounds showed good antimicrobial activities



Farshori et al synthesized a novel series of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-thiadiazoles and screened for their antimicrobial activity against *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Streptococcus pyogenes* and *Klebsiella pneumoniae* bacterial strains by disc diffusion method. Minimum inhibitory concentrations (MICs) were determined by broth dilution techniques which were in range of 6.25-12.5 µg/ml by using Chloramphenicol and Griseofulvin as standard antimicrobial drugs. Most of the tested compounds depicted excellent antimicrobial activities on comparison with standard drugs.




Foroumadi et al synthesized a series of N-[5-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole-2-yl] and N-[5-(nitrophenyl)-1,3,4-thiadiazole-2-yl]piperazinylquinolone derivatives and evaluated for *in vitro* antibacterial activity against some gram-positive and Gram-negative bacteria. The antibacterial data revealed that all nitroimidazole derivatives showed interesting activity against tested gram-positive bacteria (MIC=0.008-0.03 µg/ml) while they did not show good activity against gram-negative organisms. All nitrophenyl analogues were inactive. Among all of the tested compounds (Ciprofloxacin derivative in nitroimidazole series) exhibited excellent activity against *Staphylococcus aureus* and *Staphylococcus epidermidis* (MIC=0.008 µg/ml).




Karabasanagouda et al. synthesized some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles which were screened for their antibacterial activity against *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* bacterial strains and for antifungal activity against *Aspergillus flavus*, *Aspergillus fumigatus*, *Penicillium marneffeii* and *Trichophyton mentagrophytes*. One compound with methyl substitution was found to be the most potent compound of the series by having MIC value of 6.25 µg/ml on comparison with Ciprofloxacin and cyclopiroxolamine as standard drug. The good activity is attributed to the presence of pharmacologically active -CH₃, OCH₃, NH₂, and 2,3- dichloro groups

attached to phenyl group at position 6 of thethiadiazole ring. Results of antifungal screening showed that the presence of S-CH₃ and S-C₂H₅ groups at position 4 of phenoxy group caused increased activity.




R- 2-Cl; 4-CH₃; 4-OCH₃; 2,3-(Cl)₂; 4-NH₂


Pintilie et al synthesized some novel N-(5-(3-(methylthio)propyl)-1,3,4-thiadiazol-2yl)benzamide derivatives and investigated for their antimicrobial activities against five standard bacterial strains *Staphylococcus aureus*, *Bacillus anthracis*, *Bacillus cereus*, *Sarcinalutea* and *Escherichia coli* by using double dilution method. Some of the investigated compounds exhibited excellent antimicrobial activities on comparison with their respective standard drugs. The most active compound against *B. anthracis* and *B. cereus* was a compound with a 4-methylphenyl moiety on the heterocyclic ring.



Dubey et al synthesized 1,3,4 thiadiazole-1,3,5-triazine derivatives and evaluated their antimicrobial activity against bacterial strains like *Pseudomonas aeruginosa*, *Bacillus cereus*, *Escherichia coli* and *Bacillus subtilis*. Compounds with chloro-substitution on phenyl amine position connected to 1,3,5-triazine core exhibit significant activity against *Pseudomonas aeruginosa* (6.25 µg/mL), moderate activity against *Bacillus cereus* and *Escherichia coli* (12.5 µg/mL).




Seelam et al synthesized a novel series of 1, 3, 4-thiadiazoles which are incorporated with isoxazolo-thiazole moieties and screened for their antimicrobial activity. The screened compounds with chlorine substituted showed high antibacterial activity against all the strains against *B. subtilis* and *B. thuringiensis* with MIC 3.125 µg/ml as compared with standard drug Streptomycin. Compound having 4-OCH₃ showed equipotent activity to treflucan against all the strains *C. albicans*, *fabae*, *F. oxysporum* (MIC, 3.125 µg/ml).



R- 4-Cl; 2-Cl; 4-N(Me)₂; 3-NO₂; 4-OCH₃; 4-CH₃


Atta et al synthesized novel imidazo[2,1-b]-1,3,4-thiadiazoles and evaluated for their antimicrobial activity against *Staphylococcus aureus*, *Candida albicans*, *Pseudomonas aeruginosa* and *Escherichia coli* using agar diffusion method. Ampicillin and Clotrimazole were used as reference drugs.



X- H; Br; Cl; I


Y- H; Br; Cl

Noolvi et al synthesized 2-(4-formyl-2-methoxyphenoxy) acetic acid and screened for their antimicrobial activity against *S. aureus*, *S. enterica*, *V. cholera*, and antifungal activity against *C. albicans*.




R- H; 2-OCH₃; 3-NO₂; 4-NO₂; 4-Cl; 4-NH₂; 2,4-diOH; 4-OH; 3-CH₃

Bhardwaj et al synthesized new pyridine imidazo[2,1b]-1,3,4-thiadiazole derivatives and screened for their antimicrobial activity using cup-plate agar diffusion method against bacteria *B. pumillus*, *S. aureus*, *V. cholera*, *E. coli*, *P. mirabilis*, and *P. aeruginosa* and fungal culture of *C. albicans*. Some compound showed excellent inhibition of *B. pumillus*(95.1%), *P. aeruginosa*(94.6%), *V. cholera* (91.0%), *S. aureus*(88.8%), and one compound demonstrated inhibition of *P. mirabilis* (87.8%) when compared with standard drug Ampicillin and Amphotericin B.




R- 2,4-diOH; 2-OH; 4-CH₃; 4-NO₂; 3,4-diCH₃

Al-Qawasmeh et. Al., synthesized 9-cyclopropyl-4-fluoro-6-oxo-6,9-dihydro-[1,2,5]thiadiazolo[3,4-h]quinoline-7-carboxylic acid and ethyl ester derivatives and tested for their antimicrobial activities *in vitro* against a wide spectrum of Gram-positive and Gram-negative bacteria, yeasts and moulds taking Ciprofloxacin as reference drug. Most of the compounds were active but one compound showed excellent activity against Gram-positive bacilli and staphylococci (MICs= 0.015-1.5µg/mL), including methicillin-resistant *Staphylococcus aureus*, and against most of the Gram-negative bacteria tested (MICs = 0.07-3 µg/mL).




Gopalakrishnan et al synthesized 5,7-diaryl-4,4-dimethyl-4,5,6,7-tetrahydropyridine [3,4-d]-1,2,3thiadiazoles. All of the newly synthesized novel target molecules were tested for their antibacterial activity *in vitro* against *Staphylococcus aureus*, β-Haemolytic streptococcus, *Vibrio cholerae*, *Salmonella typhi*, *Shigella flexneri*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas* by using Ciprofloxacin as standard drug for comparison. Synthesized compounds exerted a wide range of modest antibacterial activity and modest *in vitro* antifungal activity against *Rhizopus* and *M. Gypseum*, compared to the standard drug Fluconazole.



X= halogens

Liesen et al synthesized N-(4-methoxyphenyl)-5-(5-methyl-1H-imidazol-4-yl)-1,3,4-thiadiazole-2-amine derivatives. One compound was found to be the most potent compound


with MIC value 130µg/ml as compared with standard drug Chloramphenicol and Rifampicin for antibacterial activity.



R- H; Cl; F;

OCH₃

Murthy et al supported the synthesis of some new (3,5-dichloro-4-((5-aryl-1,3,4-thiadiazol-2yl)methoxy)phenyl)aryl methanones and investigated for their antimicrobial activities by agar well diffusion method. Gentamicin (antibacterial drug) and Nystatin (antifungal drug) were used for comparison. The compound with methyl substitution was found to exhibit significant antibacterial activity at lower concentration, against Gram positive bacteria such as *Bacillus subtilis*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Bacillus cereus* and Gram negative bacteria such as *E.coli*, *Pseudomonas aeruginosa*, *Salmonella typhi*, and *Klebsiella pneumonia*. Results indicate that the compound with electron-donating groups exhibited broad spectrum antimicrobial activity against both bacteria and fungi.



COVID-19: Drug targets and potential treatments

All CoVs enzymes and proteins involved in viral replication are potential drug targets in the search for therapeutic options for SARS-CoV-2. This review provides an overview of the main targets from a structural point of view, together with reported therapeutic compounds with activity against SARS-CoV-2 and/or other CoVs. Also, the role of immune response to coronavirus infection and the related therapeutic options are presented (reference provided).

This novel CoV belongs to the Coronaviridae family as well as SARS CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV). Highly pathogenic CoVs are enveloped, positive polarity single-stranded RNA betacoronavirus and their genomes encode non-structural proteins (nsps), structural proteins and several accessory proteins.

The SARS-CoV-2 infection process starts with the viral entry mediated by the interaction of the spike (S) glycoprotein with the host angiotensin-converting enzyme 2 (ACE2) receptor,

and the S protein cleavage by the host transmembrane serine protease 2 (TMPRSS2) prior to the fusion to the host cell membrane. SARS-CoV-2 infection is profoundly inhibited with lysosomotropic drugs (99% and 98% respectively) in cells transduced with pseudovirus.





Fig 1: SARS-Cov-2 Infection Cycle

Systemic peptide mapping on SARS-CoV allowed to discover the peptide CP-1, which binds with high affinity the heptad-repeat 2 region of S2 and interferes with the conformational changes leading to the 6-helix bundle formation and thus blocking Virus cell fusion process. Recently, a pan-coronavirus fusion inhibitor lipopeptide (EK1C4) has been designed, targeting a structure formed by two specific regions in the S2 subunit.



GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE

Compounds and Peptides directed to S- Protein




Fig 2: RdRp inhibitors active against SARS-CoV-2 and under clinical trials

Host-based druggable targets :

In SARS-CoV-2, the angiotensin I converting enzyme 2 (ACE2) has been recently confirmed as the main virus receptor. Therefore, inhibition or modulation of ACE2 represents one of the proposed host-based strategies for treatment of SARS CoV-2. ACE2 can be found in epithelial cells of lung, liver and testis. ACE2 was already known for mediating infection of the less pathogenic SARS-CoV, in particular, by recognizing the receptor-binding domain of the S protein (S1 RBD) with an helical region located in the peptidase domain.

The host cell surface transmembrane serine protease 2 (TMPRSS2) activates S protein present in the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV.1.




Fig 3: TMPRSS2 modulators. A) Chemical structure of TMPRSS2 inhibitors. B) Some transcriptional inhibitors of TMPRSS2

The adaptor-associated kinase 1 (AAK1) and cyclin G-associated kinase (GAK) are host Y8 protein kinases that regulate intracellular viral trafficking during entry, assembly and release of multiple unrelated RNA viruses such as rabies, Ebola, dengue or hepatitis C virus. In the recent past, repurposing marketed drugs or optimizing valuable hits such as 3,5-disubstituted-pyrrolo[2,3-b]pyridines as potent AAK1 and GAK inhibitors could be a good strategy to avoid SARS-CoV-2 entry.




Fig 4: AAK1 and GAK inhibitors with therapeutic potential for COVID-19

The two-pore channels (TPC1-3) regulate the conductance of sodium and calcium ions across cellular membranes. These are involved in the regulation of endolysosomal trafficking and Ebola entry in the host cell.




Fig 5: Clinical used drugs blockers of TPC2. A) Dopamine antagonists, B) SERMs

Therapeutic targeting of the innate immune response:

It has been known that a cytokine storm results from an overreaction of the immune system in SARS and MERS patients. Clinical findings showed exuberant inflammatory responses during SARS-CoV-2 infection, further resulting in uncontrolled pulmonary inflammation, likely leading case fatality. The repurposing of host-based therapeutics to control immune response may counterattack COVID-19. Some of these treatments include the use of recombinant IFN- α and IFN- γ as antiviral cytokines that inhibit viral replication in targeted cells. Some studies have reported that IFN- α alone has more effect against SARS-CoV-2 than IFN- α *in vitro*. In fact, combinations of IFN- α and IFN- γ with other antivirals such as ribavirin and/or lopinavir/ritonavir (HIV treatment) have a synergistic effect *in vitro* and in animal

models. *In vitro* and *in vivo* studies show the protective effect of Type III IFN 2L₃ treatment against SARS-CoV infection, that possibly in combination with IFN-I- could be an effective treatment for SARS-CoV-2. It has been shown recently that the potential benefits from low-dose corticosteroids treatment in SARS-CoV-2 critically ill patients. Another immunosuppressor, tocilizumab, an humanized monoclonal antibody against the interleukin IL-6 receptor reduces proinflammatory response in COVID-19 patients. Immunosuppressor treatments successfully used against other viruses, could be also used for COVID-19. These would include JAK inhibitors such as tofacitinib, baricitinib, and the recently approved upadacitinib, previously used in rheumatoid arthritis blinatumomab and HDAC inhibitors such as vorinostat or belinostat. Baricitinib is also a potent inhibitor of AAK1 and may also influence in decreasing viral infectivity, being a good candidate for clinical trials of COVID-19.




Fig 6: Immunosuppression potential treatments. A) antiviral used in combination with IFN- α and IFN- β B) JAK inhibitors, C) HDAC inhibitors.




Fig 7: Anti-IFV-A agents with potential therapeutic effects on SARS-CoV-2.

Therapeutic options in clinical trials for COVID-19:

Antivirals lopinavir/ritonavir have been recommended for clinical treatment for COVID-19. However, recent results from clinical trials do not confirm any benefit in hospitalized adult patients with severe COVID-19, but the combination of these two antivirals with interferon is

found to be more promising for patients. Remdesivir is an adenosine analogue RdRp inhibitor with antiviral protection against SARS-CoV-2 and other viruses. Intravenous administration has been found to be efficacious in an American patient with COVID 19. Based on these results, Gilead Company provided the compound to China to perform the first clinical trials in SARS-CoV-2-infected individuals (Clinical trials NCT04257654/6). The FDA has approved the emergency use of this drug for COVID-19 patients with severe symptoms. Arbidol (umifenovir) is able to block viral fusion against influenza viruses. The antiviral activity of umifenovir against SARS-CoV-2 has been confirmed *in vitro*. First clinical data from patients with laboratory-confirmed COVID-19 points to a superior efficacy of umifenovir monotherapy to lopinavir/ritonavir treatment. Also, other drugs used for influenza as Avigan (favipiravir) and Tamiflu (oseltamivir) have been used in patients.




Fig 8: Antivirals used in clinic as potential COVID-19 treatment




Fig 9: Some of the approved drugs in clinical trials for COVID-19. A) Inhibitors of viral RNA polymerase, B) antipsychotics effective in clathrin-mediated endocytosis, C) miscellaneous drugs

Conclusions

In this report, we have described a brief review on the recent progress in the synthesis and biological activity studies of various Thiadiazole derivatives, an important class of heterocyclic compounds suitable as drug candidates for various drug targets.

Also focused in the present report, the structural druggable sites and determinants of antibodies efficacy against S Protein. The significance of structural spike(S) protein is remarkable due to its main role in the SARS-CoV-2 entry through the host receptor ACE2. Targeting human proteins is an excellent alternative and another promising way is the combination of available antiviral drugs acting through different targets in a multi-target strategy that has proven to increase efficacy during the recent current pandemic. It has been found during the recent pandemic that the repurposing of approved drugs is the only possibility to find a timely effective treatment. However, the coronavirus outbreaks require thorough preparedness not only for the current situation but also for a future potential reemergence of novel coronaviruses. Hence it is of utmost importance to design drugs acting

as pan-coronavirus antivirals or through a multi-target approach to avoid lack of effectiveness by viral mutation escape.

References

1. Abdelhamid AO, El Sayed IE, Hussein MZ, Mangoud MM ,Synthesis and Antimicrobial Activity of Some New Thiadiazoles, Thioamides, 5-Arylazothiazoles and Pyrimido[4,5-d][1,2,4]triazolo[4,3-a]pyrimidines. *Molecules (Basel, Switzerland)*, 17 Aug 2016, 21(8) DOI: 10.3390/molecules 21081072
- 2.M.M. Azaam, E-R. Kenawy, S.B. El-din, A.A. Khamis, M.A. El-Magd, Antioxidant and Anticancer Activities of α -Aminophosphonates Containing Thiadiazole Moiety, *Journal of Saudi Chemical Society* 22(1) (2017), June 2017. doi:10.1016/j.jscs.2017.06.002.
- 3.Noolvi, M.N. et al., Synthesis and antimicrobial evaluation of novel 1,3,4-thiadiazole derivatives of 2-(4-formyl-2-methoxyphenoxy) acetic acid. *Arabian Journal of Chemistry* (2012), doi:10.1016/j.arabjc.2012.02.
- 4.Eman M. Flefel ,Wael A. El-Sayed ,*ORCID,Ashraf M. Mohamed ORCID,Walaa I. El-Sofany, and Hanem M.Awad ,Synthesis and Anticancer Activity of New 1-Thia-4-azaspiro[4.5]decane, their Derived Thiazolopyrimidine and 1,3,4-Thiadiazole Thioglycosides *Molecules* 2017, 22(1), 170; doi.10.3390/molecules22010170.
- 5.Ameen Ali Abu-Hashem and Sami A. Al-Hussain ,Design, Synthesis of New 1,2,4-Triazole/1,3,4-Thiadiazole with Spiroindoline, Imidazo[4,5-b]quinoxaline and Thieno[2,3-d]pyrimidine from Isatin Derivatives as Anticancer Agents, *molecules*2022 Jan 27. doi: 10.3390/molecules27030835
6. Navaneetha Ramana ,Heterocyclic systems containing bridgehead nitrogen atom: Synthesis and antimicrobial activity of thiadiazolo[2',3':2,3]imidazo[4,5-B]quinoxaline, *Journal of Saudi Chemical Society* ,Feb; 27(3): 835 ,doi.org/10.1016/j.jscs.2012.12.011
- 7.Synthesis of Novel Nalidixic Acid-Based 1,3,4-Thiadiazole and 1,3,4-Oxadiazole Derivatives as Potent Antibacterial Agents ,*Chemical Biology & Drug Design*, December 2011 79(4):384-97 DOI:10.1111/j.1747-0285.2011.01316.x
- 8.Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles,*Bioorganic and medicinal chemistry* 2010 Mar 15;20(6):1933-8. doi: 10.1016/j.bmcl.2010.01.126. 1.
- 9.Vaibhav Dubey, Manish Pathak, HansR. Bhat and Udaya P. Singh*, Design, Facile Synthesis, and Antibacterial Activity of Hybrid 1,3,4-thiadiazole-1,3,5-triazine Derivatives Tethered via -S- Bridge ,*Chem Biol Drug* Dec. 2012; 80: 598–604
- 10.Nareshvarma Seelam1*,Satya P. Shrivastava and Somarouthu Prasanthi,Seelam et al., Synthesis and antimicrobial activity of some novel fused heterocyclic moieties ,*Org. Commun.* (2013) 6:2 78-85.

11. Raed al-qawasmeh, Synthesis and antibacterial activity of 9-cyclopropyl-4-fluoro-6-oxo-6,9-dihydro-[1,2,5] thiadiazolo [3,4-h] quinoline-7-carboxylic acid and its ethyl ester. *Archive for organic chemistry*, September 2009 (12):322 DOI:10.3998/ark.5550190.0010.c2.
12. Gopalakrishnan, M.; Thanusu, J.; Kanagarajan, V.; Govindaraju, R, Synthesis, antibacterial, and antifungal activities of biolabile (E)-1-(4-morpholinophenyl)-3-aryl-prop-2-en-1-ones. *Medicinal Chemistry Research* , Oct 16, 2008, Volume 18 (5) .
13. Yang H, Bartlam M, Rao Z. Drug design targeting the main protease, the Achilles' heel of coronaviruses. *Curr Pharm Des.* 2006;12:4573–90. - PubMed
14. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. *Viruses.* 2012;4:1011–33. - PMC - PubMed
15. Hilgenfeld R. From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design. *FEBS J.* 2014;281:4085–96. - PMC - PubMed
16. Chang CK, Lo SC, Wang YS, Hou MH. Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. *Drug Discov Today.* 2016;21:562–72. - PMC - PubMed
17. Paules CI, Marston HD, Fauci AS. Coronavirus infections—More than just the common cold. *JAMA.* 2020;323:707. - PubMed
18. Al-Osail AM, Al-Wazzah MJ. The history and epidemiology of Middle East respiratory syndrome corona virus. *Multidiscip Respir Med.* 2017;12:20. - PMC - PubMed
19. Alsaadi JE, Jones IM. Membrane binding proteins of coronaviruses. *Future Virology.* 2019;14:275–86.
20. McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. *Viruses.* 2014;6:2991–3018. - PMC - PubMed
21. Guo Y, Korteweg C, McNutt MA, Gu J. Pathogenetic mechanisms of severe acute respiratory syndrome. *Virus Res.* 2008;133:4–12. - PMC - PubMed
22. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. *Am J Pathol.* 2007;170:1136–47. - PMC - PubMed
23. Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications for pathogenesis and virus transmission pathways. *J Pathol.* 2004;203:622–30. - PMC - PubMed
24. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature.* 2003;426:450–4. - PMC - PubMed

25. Mubarak A, Alturaiki W, Hemida MG. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development. *J Immunol Res.* 2019;2019:1–11. - PMC - PubMed
26. te Velthuis AJ, van den Worm SH, Snijder EJ. The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension. *Nucleic Acids Res.* 2012;40:1737–47. - PMC - PubMed
27. Stobart CC, Sexton NR, Munjal H, Lu X, Molland KL, Tomar S, et al. Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity. *J Virol.* 2013;87:12611–8. - PMC - PubMed
28. Wang H, Xue S, Yang H, Chen C. Recent progress in the discovery of inhibitors targeting coronavirus proteases. *Virol Sin.* 2016;31:24–30. - PMC - PubMed
29. Hu T, Chen C, Li H, Dou Y, Zhou M, Lu D, et al. Structural basis for dimerization and RNA binding of avian infectious bronchitis virus nsp9. *Protein Sci.* 2017;26:1037–48. - PMC - PubMed
30. Bouvet M, Lugari A, Posthuma CC, Zevenhoven JC, Bernard S, Betzi S, et al. Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes. *J Biol Chem.* 2014;289:25783–96. - PMC - PubMed
31. Narayanan K, Maeda A, Maeda J, Makino S. Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. *J Virol.* 2000;74:8127–34. - PMC - PubMed
32. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. *Nat Rev Microbiol.* 2016;14:523–34. - PMC - PubMed
33. Nieto-Torres JL, Dediego ML, Alvarez E, Jiménez-Guardeño JM, Regla-Nava JA, Llorente M, et al. Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein. *Virology.* 2011;415:69–82. - PMC - PubMed
34. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. *Nat Rev Microbiol.* 2009;7:226–36. - PMC - PubMed
35. Lin SY, Liu CL, Chang YM, Zhao J, Perlman S, Hou MH. Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target. *J Med Chem.* 2014;57:2247–57. - PMC - PubMed
36. Shimamoto Y, Hattori Y, Kobayashi K, Teruya K, Sanjoh A, Nakagawa A, et al. Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CLprotease inhibitors. *Bioorg Med Chem.* 2015;23:876–90. - PMC - PubMed
37. Báez-Santos YM, Barraza SJ, Wilson MW, Agius MP, Mielech AM, Davis NM, et al. X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. *J Med Chem.* 2014;57:2393–412. - PMC - PubMed

38.Ghosh AK, Takayama J, Rao KV, Ratia K, Chaudhuri R, Mulhearn DC, et al. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: Design, synthesis, protein-ligand X-ray structure and biological evaluation. *J Med Chem.* 2010;53:4968–79. - PMC - PubMed

UNDER PEER REVIEW

39. Ratia K, Saikatendu KS, Santarsiero BD, Barretto N, Baker SC, Stevens RC, et al. Severe acute respiratory syndrome coronavirus papain-like protease: Structure of a viral deubiquitinating enzyme. *Proc Natl Acad Sci U S A*. 2006;103:5717–22. - PMC - PubMed
40. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. *Proc Natl Acad Sci U S A*. 2003;100:13190–5. - PMC - PubMed
41. Chuck CP, Chen C, Ke Z, Wan DC, Chow HF, Wong KB. Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases. *Eur J Med Chem*. 2013;59:1–6. - PMC - PubMed
42. Wang F, Chen C, Tan W, Yang K, Yang H. Structure of main protease from human coronavirus NL63: Insights for wide spectrum anti-coronavirus drug design. *Sci Rep*. 2016;6:22677. - PMC - PubMed
43. Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. *Sci Adv*. 2019;5:eaav4580. - PMC - PubMed
44. Yuan Y, Cao D, Zhang Y, Ma J, Qi J, Wang Q, et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. *Nat Commun*. 2017;8:15092. - PMC - PubMed
45. M, Song W, Zhou H, Xu J, Chen S, Xiang Y, et al. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. *Cell Res*. 2017;27:119–29. - PMC - PubMed
46. Park YJ, Walls AC, Wang Z, Sauer MM, Li W, Tortorici MA, et al. Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. *Nat Struct Mol Biol*. 2019;26:1151–7. - PMC - PubMed
47. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. *PLoS Pathog*. 2018;14:e1007236. - PMC - PubMed
48. Prabakaran P, Xiao X, Dimitrov DS. A model of the ACE2 structure and function as a SARS-CoV receptor. *Biochem Biophys Res Commun*. 2004;314:235–41. - PMC - PubMed
49. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. *Proc Natl Acad Sci U S A*. 2004;101:15748–53. - PMC - PubMed
50. Madhavi, B. and Veera Raghava Sharma, G., Studies on Thiadiazole heterocyclic compounds (Unpublished results)